Team Leader Associate Professor Greg Neely

I completed my PhD in human immunology at the University of Calgary, Canada and went on to train in functional genomics with Josef Penninger in Vienna, Austria. Since 2011 I have been running a lab in Sydney Australia using functional genomics approaches to find novel human disease genes and pathways. My main interest is in age-related diseases involving the nervous system, including pain, neurodegeneration, and strategies to extend lifespan while preserving overall health.

The Team

Dr Willie Lin - Senior Research Fellow

Sumire Antonioli- Research Technician

Mark Bugno- Honours Student

Leslie%20NC.jpg

Dr Leslie Caron - Senior Research Associate and Chong Fellow

Teleri Clark - Research Assistant

Zina Hamoudi - Research Assistant

Dr Thang Khuong - Postdoctoral Research Associate

Dr Raymond Lau - Postdoctoral Research Associate

Dr Lipin Loo - Senior Research Associate and Chong Fellow

Jaimie B. Littleboy - Research Assistant

John Manion - PhD Student

Joshua Massingham - Research Technician

Dr. Arjun Muralidharan - Postdoctoral Research Associate

Lisa Oyston - Postdoctoral Research Associate

Dr Dongzhi Ran - Postdoctoral Research Associate

Sydney Genome Initiative

Felicity Chung - Research Assistant

Sergey%27s photo for website.JPG

Dr Sergey Kurdyukov - Research Fellow - Genome Editing Specialist

Neely Lab

Our lab is focused on the systematic functional annotation of the genome. The long-term objective of our research is to identify genes and coding mutations that participate in major age-related and neurological diseases. Our overall research strategy is to combine human population genomics (GWAS or sequencing) data with high throughput functional validation in fruit flies and mammalian systems to identify new genes that contribute to human disease.

We have developed novel functional genomics strategies that we use to identify genes involved in various normal or disease states. Currently we have projects that relate to heart function, pain perception, neurodegeneration, lifespan and metabolic disorders, kidney function, and cancer. In the end our goal is to rapidly improve patient treatment, and many of the new genes we have identified appear to be viable drug targets.